logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Promoting the use of biomarkers improves cancer diagnosis and treatment

A new study evaluates the availability, quality and reimbursement of these tests in the European Union

It proposes short and long-term measures to move towards precision medicine that improves, even changes, the prognosis of the disease for many cancer patients

Source: www.farmaindustria.es

Personalized medicine is here to stay and no one doubts that the future of healthcare passes through it. The adaptation of clinical practice and, specifically, of treatments to each type of patient according to their molecular characteristics is a reality and is giving hopeful results for many patients.

This precision medicine is especially useful in the oncology area, after discovering that cancer is not a disease, but hundreds of different and differentiated pathologies that manifest and develop differently depending on the person affected.

In this sense, tumor biomarker tests are essential tools in the diagnosis and treatment of cancer. They can be used to provide accurate diagnoses and identify patients most likely to respond to treatment. They can also help predict and monitor disease progression and identify patients at highest risk for developing a certain condition.

The use of biomarkers (biological characteristics of the body that can be objectively measured and quantified: any gene, molecule or characteristic derived from tissues or body fluids, including blood), therefore, has become one of the most important clinical tools for patients. oncologists and the development of new therapies. And its spread has significant potential to transform the course of the disease.

This is pointed out by a new study promoted by the International Network for Quality in Pathology (IQN Path), the European Coalition of Cancer Patients (ECPC) and the European Federation of Pharmaceutical Industry Associations (Efpia) and entitled Boost the potential of precision medicine in Europe.

The study presents the results of research conducted in 2020 to assess the availability, quality, and reimbursement of biomarker tests in the European Union (EU), identify country-specific gaps, and develop policy recommendations to improve equitable access and the quality of these tests on the continent.

To provide an improvement in the access and quality of these tests in the EU, the study makes short-term and long-term recommendations to contribute to the transition to comprehensive and continuous tumor testing for all patients with a diagnosis of cancer.

Proposals to move forward

Parallel approval of the drug and associated tests, adoption of a national system for evaluating the value of biomarker tests, increased budget to finance them, training of managers, healthcare professionals and patients, centralized data collection and exploration of new horizons in this precision medicine are some of the short-term recommendations described in the study. As for the longer-term vision, the report suggests creating a centralized testing infrastructure, harmonized approaches throughout the testing development process, data sharing, and clear guidelines on comprehensive testing.

“The EU cancer plan sets out an ambitious vision: to harness new technologies, research and innovation and establish a new approach to cancer prevention, treatment and care. We consider this study to be an important contribution to these efforts, ”says Kathi Apostolidis, member of the ECPC Board of Directors. “One of the key recommendations of the study is to educate physicians, taxpayers, regulators, legislators and, above all, patients about the benefits of biomarker testing. Patients need this knowledge to better understand their condition and have more voice in their treatments, ”adds Ken Mastris, president of the ECPC.

Nathalie Moll, CEO of Efpia, stresses that “there are many reasons to be optimistic about the future of cancer treatment. The development of medicine in oncology is evolving rapidly, thanks to a better understanding of the underlying genetic causes of cancer. However, we cannot afford to be complacent. Cancer incidence is increasing across Europe. Therefore, there is an urgent need to provide physicians and healthcare systems with the necessary infrastructures and resources to deliver the benefits of these therapeutic advances to patients and to ensure that the pace of innovation can be maintained. This study is a solid first step in that direction and we look forward to working with all health and policy stakeholders to make this a reality. ”

 

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.